The level of galactose-deficient IgA1 in the sera of patients with IgA nephropathy is associated with disease progression - Wikidata - wikimedia - TriplyDB

The level of galactose-deficient IgA1 in the sera of patients with IgA nephropathy is associated with disease progression

The level of galactose-deficient IgA1 in the sera of patients with IgA nephropathy is associated with disease progression

http://www.wikidata.org/entity/Q36237466

about

The Origin and Activities of IgA1-Containing Immune Complexes in IgA Nephropathy New developments in the genetics, pathogenesis, and therapy of IgA nephropathy Effect of Immunosuppressive Drugs on the Changes of Serum Galactose-Deficient IgA1 in Patients with IgA Nephropathy Association of C4d deposition with clinical outcomes in IgA nephropathy.Cumulative effects of variants identified by genome-wide association studies in IgA nephropathy.Astragalus membranaceus up-regulate Cosmc expression and reverse IgA dys-glycosylation in IgA nephropathy.The genetics and immunobiology of IgA nephropathy.Identification of distinct glycoforms of IgA1 in plasma from patients with immunoglobulin A (IgA) nephropathy and healthy individuals Dual involvement of growth arrest-specific gene 6 in the early phase of human IgA nephropathy Variants in Complement Factor H and Complement Factor H-Related Protein Genes, CFHR3 and CFHR1, Affect Complement Activation in IgA Nephropathy Implication of urinary complement factor H in the progression of immunoglobulin A nephropathy.Aberrant IgA1 Glycosylation in IgA Nephropathy: A Systematic Review.New Insights into the Pathogenesis of IgA Nephropathy.GWAS for serum galactose-deficient IgA1 implicates critical genes of the O-glycosylation pathway Update on immunoglobulin a nephropathy. Part II: Clinical, diagnostic and therapeutical aspects.Primary glomerulonephritis: A review of important recent discoveries.Increased APRIL Expression Induces IgA1 Aberrant Glycosylation in IgA Nephropathy Elevated Plasma α-Defensins (HNP1-3) Levels Correlated with IgA1 Glycosylation and Susceptibility to IgA Nephropathy Toward Noninvasive Diagnosis of IgA Nephropathy: A Pilot Urinary Metabolomic and Proteomic Study.Pathogenesis of immunoglobulin A nephropathy: recent insight from genetic studies.Cytokines alter IgA1 O-glycosylation by dysregulating C1GalT1 and ST6GalNAc-II enzymes.Progression of IgA nephropathy under current therapy regimen in a Chinese population.Glomerular diseases: emerging tests and therapies for IgA nephropathy Novel biomarkers in glomerular disease.Association of systemic lupus erythematosus susceptibility genes with IgA nephropathy in a Chinese cohort Plasma Gelsolin Induced Glomerular Fibrosis via the TGF-β1/Smads Signal Transduction Pathway in IgA Nephropathy.Biomarkers in IgA nephropathy: relationship to pathogenetic hits.Cellular signaling and production of galactose-deficient IgA1 in IgA nephropathy, an autoimmune disease.Diagnosis and activity assessment of immunoglobulin A nephropathy: current perspectives on noninvasive testing with aberrantly glycosylated immunoglobulin A-related biomarkers.Biomarkers in IgA nephropathy.Paradigm shift in activity assessment of IgA nephropathy - optimizing the next generation of diagnostic and therapeutic maneuvers via glycan targeting.Proteomic biomarkers in kidney disease: issues in development and implementation.Recent advances in the understanding of immune-mediated nephrotic syndrome: diagnostic and prognostic implications.Novel Biomarkers for Renal Diseases? None for the Moment (but One).Markers for the progression of IgA nephropathy.Why, when and how should immunosuppressive therapy considered in patients with immunoglobulin A nephropathy?IgA nephropathy enigma.Inflammation in IgA nephropathy.Update on immunoglobulin A nephropathy, Part I: Pathophysiology.Pathogenic role of glycan-specific IgG antibodies in IgA nephropathy.

P2860

Q26752555-C02F1CB3-A588-472D-B9B7-3D3944073F53 Q26786248-E5C74CB7-8F09-41B1-B2DF-F7033599EB28 Q28554822-CAE33AA2-E4CB-48FB-8BB7-B41D6803CCAF Q33571848-16D8AC62-3A84-45A6-8D25-5870AC18B63C Q33585514-13364447-D894-4361-85C0-0402585BB03D Q33804357-175C750D-BB4E-41AF-8F3D-8D7904C4CE3E Q33872517-E2C66093-6904-49BB-BFEA-070F1E2A94CF Q34468379-AABE548D-45DA-4649-92F8-D74B5F74DB1D Q34795932-93BE3D31-A26C-4116-B219-92A4745BBFB0 Q35550560-BE52F8D5-3DE2-492B-8A58-9C529A1F04E3 Q35649890-72A4D4EA-0FE7-4B9C-B95E-611CA09F737B Q36199715-08A79617-7328-49F4-954C-E3FE905F7E78 Q36267833-D925190D-721D-4648-835C-BE84ED14A9AD Q36276884-45C53A0D-B284-4228-9B02-3F6224EF712B Q36447934-736069E7-07F2-4FEE-B6CF-938A70B48D9A Q36465902-70C4D66E-A909-46F6-80B6-0A7CD1A580E1 Q36822845-E2DE65C5-50D8-47E1-942E-5001B3C51128 Q37176853-3490B19E-E84F-47D8-AB21-9D27320D3CF0 Q37359092-804A847E-CE70-49CC-B29B-589222C63E45 Q37578868-2C469169-6298-4AE3-91DC-30568D5B34D5 Q37596411-0491B28C-B329-4220-BC3D-A6C0883F5249 Q37621529-04305003-C2C8-407B-B982-D2522E1C4A41 Q37621563-5ADAA360-DF92-495B-9D28-F73E999D4EF9 Q37658483-767848F7-D7B1-49E7-87C2-6CD62751AE2E Q37682219-8F809456-8E03-4DDD-801E-B9FC21AE69BC Q37690933-34683C59-5CE7-4534-AD44-8FAF7E4EDB64 Q38157013-64759968-2C00-4F01-A931-E88D45904861 Q38242833-C0386920-44F6-415C-A1E5-47BE71794882 Q38266027-CF76BEBF-835C-44ED-8FCB-0EB390E9385A Q38294669-393A6F59-6FC6-406F-B827-4585CC2AC155 Q38325438-EF38F338-54EC-46E6-A9DC-41DCB6F197A8 Q38341211-CE698131-DD0C-4410-8C5A-413AD356BDEE Q38371343-2C4398E5-8FF6-4A4D-B602-CF6D8826B2CC Q38763898-4F3276F5-4B92-4F26-A430-678637245423 Q38824816-6B214975-3548-4A00-81B8-7B30E017326A Q38860793-ED0EA8B8-FB65-4A38-8C23-8CA62E0A44DA Q38904812-F69CDEC5-9CCA-4B51-B72A-B61087D76D0E Q39178756-10737D77-C808-41B8-B5ED-BF20BBA73C58 Q40994669-A2CB3A97-8A6E-47CC-8076-8D0C35E08CD7 Q42288104-B1E2595C-6603-4EC9-BBE4-8D19455AE704

P2860

The level of galactose-deficient IgA1 in the sera of patients with IgA nephropathy is associated with disease progression

http://www.wikidata.org/entity/Q36237466

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

The level of galactose-deficie ...... iated with disease progression

@ast

The level of galactose-deficie ...... iated with disease progression

@en

type

label

The level of galactose-deficie ...... iated with disease progression

@ast

The level of galactose-deficie ...... iated with disease progression

@en

prefLabel

The level of galactose-deficie ...... iated with disease progression

@ast

The level of galactose-deficie ...... iated with disease progression

@en

P1433

Q36237466-C1B60097-1D12-43D0-B51A-8298F6227CF1

P1476

Q36237466-5733A813-BCA2-4D99-ADD7-E9AAE8E4FB26

P2093

Q36237466-27F2BF72-EAF9-43AB-A0DC-56B474A4DAE8

Q36237466-2DEDAFE7-0933-41E7-BA50-6DD0CEC69C40

Q36237466-35CD0BC1-FCAC-4B91-975B-237C812F57BE

Q36237466-6EE5FAD9-B543-4CD9-8A00-CDCEA007B011

Q36237466-70024D7B-57B0-4D26-9D86-D8B9F729644C

Q36237466-7E29E677-0AC0-44E3-B6EF-FF6F0C13EFF6

Q36237466-A9D47FA7-9D08-4319-AEE1-B30C09DAAC1D

Q36237466-F7182BD0-ABD8-4C03-83A8-F7D6B0FABF95

P2860

Q36237466-0DD3D184-40A7-4F2E-874A-3BF455F9E5AD

Q36237466-25F66071-044D-4EE7-906F-AEF37DF11098

Q36237466-266EAFDD-EBD4-453A-B362-73312A6E777D

Q36237466-28DD3C1D-B194-4867-B98D-7167D924E2FD

Q36237466-2E4D631C-BD19-40B2-9579-FB46AE5650F1

Q36237466-3124566F-0E6E-482E-8E9C-A9027109F3C9

Q36237466-47C8B64F-3390-450B-B24B-25BCD03B8836

Q36237466-4B9047EC-8DE3-4839-A941-CEC483E26F4D

Q36237466-4E88FA84-7407-455F-A628-6105B5D5575C

Q36237466-50A22CEC-9126-4528-AC86-30D043A1BCFF

P2888

Q36237466-BCF9C5B5-A926-4795-9441-269DD95A10E6

P304

Q36237466-8B14C56B-2F53-42FB-B64E-670515693423

P31

Q36237466-8CD7EA94-CE67-4A76-AA46-CD1028E8446E

P356

Q36237466-B54A3FC3-5E61-4DCA-986D-B2718824B568

P407

Q36237466-4FDDAE63-A7CE-41C2-AC47-C4DC8EA6C992

P433

Q36237466-78563B67-A2DD-4892-8C8F-EE02E1E50EFB

P478

Q36237466-76438123-F88A-43B4-BB49-35EEF77326B5

P50

Q36237466-DE463795-DFA1-43E7-B206-813322B371EB

P577

Q36237466-70DAB7BF-ED82-456C-A71D-1DBD625F2A9C

P5875

Q36237466-5CB8079F-416B-4981-BCE7-1D49B2D67BCA

P698

Q36237466-90053AAE-C4DD-4D2A-A28D-03498F8E5DA4

P921

Q36237466-8EE1B4AC-0A9C-4027-999C-312929B8F82C

P932

Q36237466-588FFFAD-5FA2-47BC-9ABE-B315F9589365

P356

P1433

Kidney International

P1476

The level of galactose-deficie ...... iated with disease progression

@en

P2093

Ali G Gharavi

http://www.w3.org/2001/XMLSchema#string

Hong Zhang

http://www.w3.org/2001/XMLSchema#string

Jan Novak

http://www.w3.org/2001/XMLSchema#string

Jicheng Lv

http://www.w3.org/2001/XMLSchema#string

Krzysztof Kiryluk

http://www.w3.org/2001/XMLSchema#string

Na Zhao

http://www.w3.org/2001/XMLSchema#string

Ping Hou

http://www.w3.org/2001/XMLSchema#string

Zina Moldoveanu

http://www.w3.org/2001/XMLSchema#string

P2860

The pathophysiology of IgA nephropathy

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

Mass spectrometry proves under-O-glycosylation of glomerular IgA1 in IgA nephropathy.

Heterogeneity of O-glycosylation in the hinge region of human IgA1.

Comparison of methods for profiling O-glycosylation: Human Proteome Organisation Human Disease Glycomics/Proteome Initiative multi-institutional study of IgA1

Predicting progression in IgA nephropathy.

Clustered O-glycans of IgA1: defining macro- and microheterogeneity by use of electron capture/transfer dissociation.

O-glycosylation of serum IgA1 antibodies against mucosal and systemic antigens in IgA nephropathy.

Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity

Aberrant IgA1 glycosylation is inherited in familial and sporadic IgA nephropathy.

P2888

P304

790-796

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/KI.2012.197

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

82

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-06-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

225279057

http://www.w3.org/2001/XMLSchema#string

P698

22673888

http://www.w3.org/2001/XMLSchema#string

P921

P932

3443545

http://www.w3.org/2001/XMLSchema#string